Repligen Co. (NASDAQ:RGEN) Shares Purchased by State of New Jersey Common Pension Fund D

State of New Jersey Common Pension Fund D raised its position in Repligen Co. (NASDAQ:RGEN) by 2.0% during the 3rd quarter, according to its most recent disclosure with the SEC. The fund owned 19,700 shares of the biotechnology company’s stock after purchasing an additional 382 shares during the period. State of New Jersey Common Pension Fund D’s holdings in Repligen were worth $2,932,000 at the end of the most recent reporting period.

Other hedge funds have also made changes to their positions in the company. Mitsubishi UFJ Asset Management Co. Ltd. grew its stake in Repligen by 30.2% in the 1st quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 28,883 shares of the biotechnology company’s stock valued at $5,312,000 after acquiring an additional 6,705 shares during the last quarter. Swedbank AB acquired a new stake in shares of Repligen in the first quarter valued at approximately $5,518,000. Banque Pictet & Cie SA increased its stake in shares of Repligen by 74.6% during the 2nd quarter. Banque Pictet & Cie SA now owns 34,515 shares of the biotechnology company’s stock worth $4,351,000 after purchasing an additional 14,746 shares in the last quarter. Vanguard Group Inc. raised its position in shares of Repligen by 0.4% during the 1st quarter. Vanguard Group Inc. now owns 5,100,013 shares of the biotechnology company’s stock worth $937,994,000 after purchasing an additional 21,719 shares during the last quarter. Finally, Diversified Trust Co lifted its stake in Repligen by 3.7% in the 2nd quarter. Diversified Trust Co now owns 2,949 shares of the biotechnology company’s stock valued at $372,000 after buying an additional 106 shares in the last quarter. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Repligen Stock Performance

NASDAQ:RGEN opened at $150.47 on Thursday. The company has a market cap of $8.43 billion, a P/E ratio of -406.66, a P/E/G ratio of 4.27 and a beta of 0.96. The firm’s 50 day moving average is $141.59 and its two-hundred day moving average is $144.78. Repligen Co. has a fifty-two week low of $113.50 and a fifty-two week high of $211.13. The company has a quick ratio of 5.56, a current ratio of 6.65 and a debt-to-equity ratio of 0.26.

Repligen (NASDAQ:RGEN) last issued its earnings results on Tuesday, November 12th. The biotechnology company reported $0.43 earnings per share for the quarter, topping the consensus estimate of $0.34 by $0.09. Repligen had a positive return on equity of 3.92% and a negative net margin of 3.36%. The business had revenue of $154.87 million for the quarter, compared to analyst estimates of $153.34 million. During the same period last year, the company posted $0.23 EPS. The business’s quarterly revenue was up 9.7% on a year-over-year basis. Analysts expect that Repligen Co. will post 1.45 EPS for the current year.

Insider Buying and Selling

In other Repligen news, Director Anthony Hunt sold 22,191 shares of the business’s stock in a transaction that occurred on Tuesday, September 10th. The shares were sold at an average price of $145.37, for a total transaction of $3,225,905.67. Following the completion of the sale, the director now directly owns 139,840 shares in the company, valued at $20,328,540.80. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 1.20% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts have weighed in on the company. Stephens reissued an “overweight” rating and set a $170.00 price target on shares of Repligen in a research report on Tuesday, July 30th. JPMorgan Chase & Co. boosted their target price on shares of Repligen from $190.00 to $200.00 and gave the company an “overweight” rating in a research note on Wednesday, July 31st. Benchmark restated a “hold” rating on shares of Repligen in a report on Monday, August 5th. Royal Bank of Canada reiterated an “outperform” rating and set a $205.00 price target on shares of Repligen in a report on Thursday, September 26th. Finally, StockNews.com raised shares of Repligen from a “sell” rating to a “hold” rating in a research note on Wednesday. Three investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. According to data from MarketBeat, Repligen presently has an average rating of “Moderate Buy” and a consensus target price of $190.25.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.